About cvrx inc - CVRX
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.
CVRX At a Glance
CVRx, Inc.
9201 West Broadway Avenue
Minneapolis, Minnesota 55445
| Phone | 1-763-416-2840 | Revenue | 56.65M | |
| Industry | Medical Specialties | Net Income | -53,306,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 10.448% | |
| Fiscal Year-end | 12 / 2026 | Employees | 223 | |
| View SEC Filings |
CVRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.269 |
| Price to Book Ratio | 4.751 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.168 |
| Enterprise Value to Sales | 2.824 |
| Total Debt to Enterprise Value | 0.316 |
CVRX Efficiency
| Revenue/Employee | 254,040.359 |
| Income Per Employee | -239,040.359 |
| Receivables Turnover | 5.312 |
| Total Asset Turnover | 0.476 |
CVRX Liquidity
| Current Ratio | 7.633 |
| Quick Ratio | 6.716 |
| Cash Ratio | 5.685 |
CVRX Profitability
| Gross Margin | 83.995 |
| Operating Margin | -90.493 |
| Pretax Margin | -94.127 |
| Net Margin | -94.095 |
| Return on Assets | -44.756 |
| Return on Equity | -96.587 |
| Return on Total Capital | -59.342 |
| Return on Invested Capital | -50.604 |
CVRX Capital Structure
| Total Debt to Total Equity | 128.43 |
| Total Debt to Total Capital | 56.223 |
| Total Debt to Total Assets | 48.194 |
| Long-Term Debt to Equity | 127.535 |
| Long-Term Debt to Total Capital | 55.831 |